DK1282607T3 - Prodrugs af hiv-replikationshæmmende pyrimidiner - Google Patents

Prodrugs af hiv-replikationshæmmende pyrimidiner Download PDF

Info

Publication number
DK1282607T3
DK1282607T3 DK01933925.8T DK01933925T DK1282607T3 DK 1282607 T3 DK1282607 T3 DK 1282607T3 DK 01933925 T DK01933925 T DK 01933925T DK 1282607 T3 DK1282607 T3 DK 1282607T3
Authority
DK
Denmark
Prior art keywords
amino
formula
cyano
mono
substituted
Prior art date
Application number
DK01933925.8T
Other languages
English (en)
Inventor
Donald William Ludovici
Robert W Kavash
Corte Bart Lieven Daniel De
Paul Adriaan Jan Janssen
Lucien Maria Henricus Koymans
Aken Koen Jeanne Alfons Van
Alain Krief
Michael Joseph Kukla
Jan Heeres
Jonge Marc René De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1282607T3 publication Critical patent/DK1282607T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01933925.8T 2000-05-08 2001-05-03 Prodrugs af hiv-replikationshæmmende pyrimidiner DK1282607T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20247100P 2000-05-08 2000-05-08
PCT/EP2001/004990 WO2001085699A2 (en) 2000-05-08 2001-05-03 Prodrugs of hiv replication inhibiting pyrimidines

Publications (1)

Publication Number Publication Date
DK1282607T3 true DK1282607T3 (da) 2016-02-01

Family

ID=22749996

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01933925.8T DK1282607T3 (da) 2000-05-08 2001-05-03 Prodrugs af hiv-replikationshæmmende pyrimidiner

Country Status (14)

Country Link
US (2) US7034019B2 (da)
EP (1) EP1282607B1 (da)
JP (1) JP4969010B2 (da)
AR (1) AR035573A1 (da)
AU (1) AU782948B2 (da)
CA (1) CA2407754C (da)
DK (1) DK1282607T3 (da)
ES (1) ES2559273T3 (da)
JO (1) JO3079B1 (da)
MY (1) MY136671A (da)
PA (1) PA8516501A1 (da)
SA (1) SA01220305B1 (da)
TW (1) TWI292395B (da)
WO (1) WO2001085699A2 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004049B1 (ru) * 1998-11-10 2003-12-25 Янссен Фармацевтика Н.В. Пиримидины, ингибирующие репликацию вич
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
AU2004283137A1 (en) 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
PL2813225T3 (pl) * 2004-09-24 2018-11-30 University Of Maryland, Baltimore Sposób leczenia zatrucia związkami fosforoorganicznymi
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US7216803B2 (en) 2005-01-21 2007-05-15 Kingsley Chukwudum Nwosu Biometric delegation and authentication of financial transactions
DK1846394T3 (da) 2005-02-04 2012-01-16 Astrazeneca Ab Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
BRPI0609291B1 (pt) * 2005-03-04 2022-02-08 Janssen Sciences Ireland Uc 2-(4-ciano-fenil)-o-hidroxilamina-pirimidinas que inibem hiv, composição farmacêutica que as compreende e processo para a preparação de ambas
KR20080015409A (ko) 2005-05-16 2008-02-19 아스트라제네카 아베 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
IN2014DN04588A (da) * 2005-05-26 2015-07-10 Tibotec Pharm Ltd
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
JP2009513615A (ja) 2005-10-28 2009-04-02 アストラゼネカ アクチボラグ 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
GEP20125691B (en) 2006-12-08 2012-11-26 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
BRPI0815715A8 (pt) 2007-08-22 2017-07-04 Irm Llc Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
EP2161259A1 (de) * 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
WO2011053701A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
EP2702044B1 (en) * 2011-04-25 2017-03-22 Hetero Research Foundation Process for rilpivirine
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
KR102090453B1 (ko) 2012-03-15 2020-03-19 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 염
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN107778255B (zh) * 2017-11-16 2019-10-25 山东大学 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
CN112546969B (zh) * 2020-12-07 2022-12-23 安徽贝克制药股份有限公司 催化加氢连续生产装置和利托那韦中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748122A (en) * 1954-05-06 1956-05-29 Searle & Co 2-anilino-4, 6-dimethylpyrimidines
DD236667A1 (de) * 1984-05-21 1986-06-18 Fahlberg List Veb Fungizide mittel, die 2-amino-pyrimidine enthalten
JPH0784445B2 (ja) 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
GB9013349D0 (en) 1990-06-14 1990-10-17 Marconi Gec Ltd Transponder system
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5834687A (en) 1995-06-07 1998-11-10 Acuson Corporation Coupling of acoustic window and lens for medical ultrasound transducers
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1163401A (zh) 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
WO1999031073A1 (fr) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de pyrimidine-5-carboxamide
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
ATE232521T1 (de) 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
EA004049B1 (ru) 1998-11-10 2003-12-25 Янссен Фармацевтика Н.В. Пиримидины, ингибирующие репликацию вич
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2003532713A (ja) 2003-11-05
CA2407754C (en) 2009-09-15
ES2559273T3 (es) 2016-02-11
WO2001085699A2 (en) 2001-11-15
US7763631B2 (en) 2010-07-27
SA01220305B1 (ar) 2007-03-10
JO3079B1 (ar) 2017-03-15
MY136671A (en) 2008-11-28
TWI292395B (en) 2008-01-11
US20030186990A1 (en) 2003-10-02
EP1282607A2 (en) 2003-02-12
AR035573A1 (es) 2004-06-16
AU6027701A (en) 2001-11-20
US7034019B2 (en) 2006-04-25
CA2407754A1 (en) 2001-11-15
WO2001085699A3 (en) 2002-02-28
US20060009474A1 (en) 2006-01-12
JP4969010B2 (ja) 2012-07-04
PA8516501A1 (es) 2002-08-26
EP1282607B1 (en) 2015-11-11
AU782948B2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
DK1282607T3 (da) Prodrugs af hiv-replikationshæmmende pyrimidiner
KR100658489B1 (ko) Ｈｉｖ 복제를 억제하는 피리미딘
JP3507917B2 (ja) Ｈｉｖを阻害するピリミジン誘導体
US6903213B2 (en) HIV inhibiting pyrimidine derivatives
AU2004274185B2 (en) HIV replication inhibiting purine derivatives
EP3808743B1 (en) Hiv replication inhibiting pyrimidines
AU5633301A (en) Hiv replication inhibitors
MXPA01003646A (en) Hiv replication inhibiting pyrimidines